Corbus Pharmaceuticals, based in Norwood, Massachusetts, focuses on developing therapies for rare inflammatory diseases and cancer, with a pipeline including CRB-701 and CRB-601. The company went public on October 24, 2014, and employs 19 staff.
Dominic Smethurst sold 6,393 shares of CRBP on 6 March at $6.78 per share, worth a total of $43K. They now own 70,807 CRBP shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
